Skip to content

For US Healthcare Professionals Only

Prescribing Information
Patient Site
Vevye Logo Vevye Logo Contact Us

Header Secondary text

Header copy at H4

Header Copy at H2

Header copy at H4

Large Copy in Bold.

Default copy in Regular, Italic, Bold and Bold Italic. Inline link style: linked here.

  • L1: Lorem ipsum odor amet, consectetuer adipiscing elit. Fusce hac tortor dignissim blandit adipiscing mi augue. 
    • L2: Lorem ipsum odor amet, consectetuer adipiscing elit. Fusce hac tortor dignissim blandit adipiscing mi augue. 
      • L3: Lorem ipsum odor amet, consectetuer adipiscing elit. Fusce hac tortor dignissim blandit adipiscing mi augue. 
  1. L1: Lorem ipsum odor amet, consectetuer adipiscing elit. Fusce hac tortor dignissim blandit adipiscing mi augue. 
    1. L2: Lorem ipsum odor amet, consectetuer adipiscing elit. Fusce hac tortor dignissim blandit adipiscing mi augue. 
      1. L3: Lorem ipsum odor amet, consectetuer adipiscing elit. Fusce hac tortor dignissim blandit adipiscing mi augue. 

INDICATION AND USAGE

VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Potential for Eye Injury and Contamination – To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.
  • Use with Contact Lenses – VEVYE should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE.

Adverse Reactions

In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about VEVYE, please see the Full Prescribing Information.